source
- Teva R&D chief Eric Hughes resigns, company taps innovative medicines head as interim leadTeva announced that its chief scientific officer for research and development, Eric Hughes, M.D., Ph.D., will leave the company. Hughes, who joined Teva in 2022 as executive vice president of globa…
- nChroma Bio cuts workforce by half and stops HBV cure trialnChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…